CurrentAmeriHealth CaritasPolicy CCP. 1552

Skin Substitutes for Chronic Wounds

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP. 1552 alerts

Get alerted when Policy CCP. 1552 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity and coverage criteria for cellular and acellular skin substitute products used as adjunctive therapy for chronic cutaneous wounds and select acute thermal burns for AmeriHealth Caritas members.

Policy Summary

PayerAmeriHealth Caritas

PolicySkin Substitutes for Chronic Wounds

Policy CodePolicy CCP. 1552

Change TypeNo material changes

Effective DateNov 1, 2025

Last ReviewNov 1, 2025

Next Review DateMar 1, 2027

Key ActionObtain prior authorization confirming a prepared wound bed, infection control, adequate perfusion, documented failure of ≥4 weeks optimized care, and alignment with product FDA labeling before applying a skin substitute.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=50%wound response threshold (4 wk)

≥50% @4wtreatment response benchmark

toe>30/TcPO2>25/SPP>40perfusion thresholds

one at a timeproduct use restriction

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmeriHealth CaritasPolicy CCP. 1552

Skin Substitutes for Chronic Wounds

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP. 1552 alerts

Get alerted when Policy CCP. 1552 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmeriHealth Caritas

PolicySkin Substitutes for Chronic Wounds

Policy CodePolicy CCP. 1552

Change TypeNo material changes

Effective DateNov 1, 2025

Last ReviewNov 1, 2025

Next Review DateMar 1, 2027

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=50%wound response threshold (4 wk)

≥50% @4wtreatment response benchmark

toe>30/TcPO2>25/SPP>40perfusion thresholds

one at a timeproduct use restriction

3–6 wksminimum duration before advanced therapy

Coverage Criteria for Skin Substitutes

inv-01: General (all indications)

Covered when ALL of the following are met:

General criteria: Partial or full-thickness cutaneous defect with a prepared wound bed (adequate debridement, clean, moisture-balanced) and no clinical signs of active infection; managing the specific cause of the wound during treatment (e.g., proven offloading for diabetic foot ulcers; sustained compression for venous leg ulcers); nutritional status assessed and optimized; objective perfusion assessment supports healing potential as defined per indication; one product used at a time; no known hypersensitivity to the product source; application technique and frequency conform to FDA-labeled instructions.

inv-02: Diabetic foot ulcers (neuropathic, non-ischemic)

Covered when ALL of the following are met in addition to general criteria:

DFU criteria: Adequate perfusion documented (suggested by toe pressure > 30 mm Hg, skin perfusion pressure > 40 mm Hg, or transcutaneous oxygen pressure > 25 mm Hg); consider urgent vascular imaging/consult if ankle pressure < 50 mm Hg, ABI < 0.5, toe pressure < 30 mm Hg, or TcPO2 < 25 mm Hg; chronic, non-infected ulcer extending through the dermis without exposed tendon/muscle/capsule/bone; failed to show >50% area reduction after >4 weeks of optimized standard care (serial debridement, moisture balance, infection control, and effective offloading); wound meets product-specific minimum chronicity per labeling (e.g., >3 weeks for Apligraf; >6 weeks for Dermagraft); glycemic management is being addressed and optimized; no untreated osteomyelitis at the ulcer site and no active Charcot process involving the ulcer surface.

inv-03: Nonhealing dermal wounds (non-pressure)

Covered when ALL of the following are met in addition to general criteria:

Non-pressure dermal wound criteria: Adequate perfusion documented (suggested by toe pressure > 30 mm Hg, skin perfusion pressure > 40 mm Hg, or transcutaneous oxygen pressure > 25 mm Hg); non-infected partial- or full-thickness traumatic, postsurgical, or ischemic venous-mixed ulcers that have failed to improve after >4 weeks of optimized care (including debridement, moisture balance, and infection control); selection should follow product labeling and objective monitoring.

inv-04: Thermal burns (acute)

Covered when ALL of the following are met in addition to general criteria:

Thermal burn criteria: Partial- or deep partial-thickness thermal burns after appropriate excision and hemostasis; no burn wound infection present; autograft is not immediately available or is being staged; products used for temporary coverage, donor-site optimization, or to reduce autograft burden consistent with product labeling and evidence.

inv-05: Venous leg ulcers

Covered when ALL of the following are met in addition to general criteria:

VLU criteria: Adequate arterial perfusion confirmed with ABI guidance (apply standard compression if ABI > 0.8; consider modified/light compression if ABI 0.5–0.8; do not initiate compression if ABI < 0.5 or > 1.3); chronic, non-infected partial- or full-thickness ulcer that has failed to show meaningful improvement (e.g., <50% area reduction) after >4 weeks of optimized standard care with sustained therapeutic compression, appropriate debridement, infection control, and moisture balance; sustained therapeutic compression must continue during treatment.

inv-06: Initial coverage criteria

Covered when ALL of the following are met

FDA labeling and population: Product use is consistent with US FDA labeling and approved indications and patient age restrictions.

Aligns use with FDA labeling per appendix purpose.

Wound type match: Wound type aligns with policy scope: diabetic foot ulcer or venous leg ulcer without exposed tendon/muscle/joint capsule/bone unless labeling permits, or thermal burns within FDA-defined depths.

Based on scope definitions.

Foundational care provided: Required foundational wound care has been delivered: for DFU — evidence-based offloading and infection control; for VLU — sustained therapeutic compression; for all wounds — adequate perfusion assessment, debridement as needed, moisture balance, and infection management.

Foundational care required prior to or concurrent with skin substitute use.

inv-07: Initial eligibility for advanced wound products

Covered when ALL of the following are met:

Initial eligibility: 1) Wound type matches the product's FDA-labeled indication (etiology, depth, anatomic limits, and patient population). 2) Foundational care is in place: for diabetic foot ulcers — evidence-based offloading and infection control; for venous leg ulcers — sustained therapeutic compression; for all wounds — adequate perfusion assessment, debridement as needed, moisture balance, and infection management. 3) Wound meets the product-specific minimum duration per FDA labeling (e.g., Apligraf ≥3 weeks; Dermagraft/Omnigraft ≥6 weeks; venous leg ulcer >1 month for Apligraf). 4) Ulcers with exposed tendon, muscle, joint capsule, or bone are eligible only if the product's FDA labeling explicitly permits use.product-specific durations

Must align with FDA labeling and documented optimized standard care.

inv-08: Continuation therapy (4-week reassessment rule)

Continue product only if following condition is met:

4-week reassessment: At four weeks after product initiation, wound area must have decreased by at least 50% to continue the same product; if not, stop treatment, reassess, and consider an alternative product class.>=50% area reduction at 4 weeks

If the FDA label requires a longer minimum duration, follow the product labeling.

inv-09: Product selection hierarchy

When selecting product classes:

Regulatory tier preference: Prefer Tier 1 products (PMA/BLA/HDE) when clinically appropriate; use Tier 2 (510(k)) devices when no Tier 1 option fits; reserve Tier 3 (361 HCT/Ps) as the lowest tier noting lack of FDA wound-etiology approval.tiered preference

Also consult wound-to-product mapping for wound characteristics and FDA labeling.

The policy excludes routine or prophylactic application of skin substitutes in settings where clinical benefit is not established. Specifically, use for routine pressure ulcer management, prophylactic application to closed intact skin, or for purely cosmetic purposes is not covered. Use on fully epithelialized wounds is not medically necessary. Simultaneous application of more than one skin substitute to the same wound is not permitted. The policy also lists clinical conditions that render use investigational or not medically necessary, including uncontrolled infection, untreated ischemia below defined thresholds, an unprepared wound bed, active vasculitides or autoimmune ulcerative conditions requiring systemic management, and known hypersensitivity to the product source. Additionally, continued use should be stopped if there is <50% area reduction after 4 weeks of product use, indicating change of approach is needed.

Chronic ulcers that expose tendon, muscle, joint capsule, or bone are outside the routine scope of covered indications unless a specific product's FDA labeling explicitly permits use in that setting. The policy restricts coverage of chronic diabetic foot ulcers and venous leg ulcers to those without exposed deep structures unless labeling provides direct authorization for such use.

The policy states that any ulcer with exposed tendon, bone, or joint capsule is not eligible for the advanced skin substitute products outlined in the wound-to-product mapping unless the product's FDA labeling explicitly permits such application. For wounds with exposed deep structures, surgical options to optimize coverage should be prioritized before considering labeled product use.

Applications of skin substitutes are not covered when foundational therapies are not documented or when active uncontrolled infection exists. For diabetic foot ulcers, absence of documented offloading removes eligibility; for venous leg ulcers, lack of sustained therapeutic compression removes eligibility. Use is also excluded for wounds with untreated ischemia below policy thresholds, an unprepared wound bed, or when there is ongoing uncontrolled infection.

Coverage for skin substitutes is contingent on prior or concurrent delivery of required foundational wound care. For diabetic foot ulcers this includes evidence-based offloading; for venous leg ulcers this includes sustained therapeutic compression. For all wounds, providers must demonstrate adequate perfusion assessment, appropriate debridement when indicated, infection management, and moisture balance before initiating advanced products.

Advanced therapies must align with product-specific minimum wound duration requirements and be preceded by optimized standard care. The policy requires adherence to FDA-labeled minimum chronicity before application (for example, Apligraf ≥3 weeks for diabetic foot ulcers and Dermagraft/Omnigraft ≥6 weeks), and notes that some indications (e.g., venous leg ulcer with Apligraf) have different minimums. Initiation of a skin substitute prior to meeting these label-specific duration thresholds or without documented optimized standard care is considered not medically necessary.

Coding and Clinical Thresholds

Regulatory product identifiers mentioned in evidence tablemixed

P950032/S016	Apligraf (diabetic foot ulcer) PMA supplemental identifier (May 22, 1998)
P000036	Dermagraft PMA identifier (Sep 28, 2001)
P900033/S042	Omnigraft PMA supplemental identifier (Jan 7, 2016)
K061711	OASIS 510(k) (Jul 19, 2006)
K083440	PriMatrix 510(k) (Dec 12, 2008)
K132343	Kerecis 510(k) (Oct 23, 2013)
STN 125730	StrataGraft BLA/STN (Jun 15, date partial)
P900033	Integra Dermal Regeneration Template PMA identifier (Jan 7, 2016)
P960007	TransCyte PMA identifier (Mar 18, 1997)
BP170122	RECELL Autologous Cell Harvesting Device PMA identifier (Sep 20, 2018)

1–10 of 13

1/2

Perfusion thresholds — toe pressure, TcPO2, SPP and ABI notes

Toe pressure / TcPO2 / SPPAdequate perfusion suggested by toe pressure > 30 mm Hg OR transcutaneous oxygen pressure (TcPO2) > 25 mm Hg OR skin perfusion pressure (SPP) > 40 mm Hg.

Urgent vascular criteriaConsider urgent vascular imaging/consultation if ankle pressure < 50 mm Hg, ankle-brachial index (ABI) < 0.5, toe pressure < 30 mm Hg, or TcPO2 < 25 mm Hg.

ABI caveat in diabetesAnkle-brachial index alone may be unreliable in diabetes and should not be the sole perfusion assessment.

Treatment response threshold — area reduction after optimized care

4‑week response benchmarkTreatment response defined as <50% reduction in wound area after more than 4 weeks of optimized standard care.

Optimized standard care components

Provider Actions, Documentation & Prior Authorization

Prior Authorization

Prior authorization required to confirm general and indication-specific criteria

Prior authorization is required to confirm that all general criteria and the indication-specific criteria are met prior to application, including a prepared wound bed (adequate debridement, clean, moisture-balanced), absence of clinical signs of active infection, objective perfusion assessment, evidence that only one product will be used at a time, and that application technique/frequency will follow the FDA-labeled instructions for the selected product.

Confirms general criteria: prepared wound bed, no active infection, nutrition assessed, perfusion supports healing.
Confirms indication-specific requirements (e.g., offloading for DFU; sustained compression for VLU).

Prior Authorization

Prior authorization: align product use with FDA labeling and foundational care

Selection and continuation of a skin substitute must match the exact FDA-labeled indication and be accompanied by demonstration that required foundational wound care is in place or planned (e.g., offloading, compression); prior authorization will be used to verify labeling-appropriate use and foundational care.

Background and Evidence Summary

Chronic wounds are defined in this policy as lesions that persist beyond the typical healing interval (generally >4–6 weeks) and that fail to respond adequately to optimized standard care. These wounds carry elevated risks including secondary infection, osteomyelitis, and potential limb loss. Skin substitutes — cellular or acellular matrices — are described as adjunctive therapies reserved for wounds that have not improved with foundational care; their use requires assessment of perfusion, control of infection, debridement as needed, and etiology-specific measures such as offloading for diabetic foot ulcers or sustained compression for venous leg ulcers.

Definitions and Regulatory Tiers

Skin substitute definition — cellular vs acellular and sources

Cellular vs acellularSkin substitutes are defined as cellular (containing living cells) or acellular (without living cells).

Source: humanHuman-derived sources include autologous or allogeneic tissues such as cadaveric dermis or placental membranes (amniotic/chorionic).

Source: non-human / syntheticNon-human (xenographic) sources include porcine or bovine tissues; synthetic or biosynthetic polymers/composites are also used.

Layer classificationProducts are categorized by the skin layers they replace (dermal, epidermal, or bilayer constructs).

Chronic ulcers (policy scope)

Included chronic ulcersChronic ulcers in scope: diabetic foot ulcers and venous leg ulcers without exposed tendon, muscle, joint capsule, or bone unless FDA labeling explicitly permits.

Policy Summary

PayerAmeriHealth Caritas

PolicySkin Substitutes for Chronic Wounds

Policy CodePolicy CCP. 1552

Change TypeNo material changes

Effective DateNov 1, 2025

Last ReviewNov 1, 2025

Next Review DateMar 1, 2027

SourceLink

On This Page

Optimized care includes serial debridement, moisture balance, infection control, and etiology-specific measures (e.g., offloading for DFU, sustained compression for VLU).

Action on nonresponseIf <50% area reduction at 4 weeks, stop and reassess; consider an alternative class or further evaluation.

Compression ABI guidance (venous leg ulcer)

Standard compressionApply standard compression if ABI > 0.8.

Modified/light compressionConsider modified or light compression if ABI 0.5–0.8.

Do not initiate compressionDo not initiate compression if ABI < 0.5 or ABI > 1.3.

Minimum Duration Before Advanced Therapy — product-dependent examples

Apligraf minimum durationApligraf for diabetic foot ulcer: at least 3 weeks per FDA labeling.

Dermagraft / Omnigraft minimumsDermagraft and Omnigraft for diabetic foot ulcers: at least 6 weeks per FDA labeling.

VLU exampleVenous leg ulcer treated with Apligraf: greater than 1 month (with sustained compression).

FDA alignment first: match etiology, depth, duration, anatomic limits, and population.
Document that foundational care (offloading, sustained compression, perfusion assessment, debridement, infection control) is provided.

Prior Authorization

Prior authorization must show FDA-label alignment and product-specific minimum duration

Prior authorization submissions must demonstrate alignment to the product's FDA-labeled indication and any product-specific minimum wound duration (for example, Apligraf ≥3 weeks; Dermagraft/Omnigraft ≥6 weeks) and include evidence of optimized standard care and a plan for four-week reassessment.

Show product-specific minimum duration per FDA labeling (e.g., Apligraf ≥3 weeks; Dermagraft/Omnigraft ≥6 weeks).
Include documentation of optimized standard care and intent to perform 4‑week reassessment for continued use.

Step Therapy

Skin substitutes are advanced therapies after failure of optimized standard care (usually ≥4 weeks)

Skin substitutes are considered adjunctive advanced therapies after failure of optimized standard care—typically following at least four weeks of optimized care—and prior authorization should reflect that step (one adjunctive product at a time).

Optimized standard care typically ≥4 weeks before escalation.
Policy expectation of one product used at a time; simultaneous products are not allowed.

Step Therapy

Foundational therapy must be provided before advanced products

Providers must document that foundational therapies were applied before initiating a skin substitute—examples include evidence-based offloading for diabetic foot ulcers and sustained therapeutic compression for venous leg ulcers.

Offloading: specialized cast, boot, or device that removes pressure for DFU.
Sustained therapeutic compression must be in place and continue during treatment for VLU.

Step Therapy

Prefer Tier 1, then Tier 2, then Tier 3 in product selection

When multiple product classes are appropriate, follow a step approach by regulatory tier: prefer Tier 1 (PMA/BLA/HDE) products when clinically appropriate, use Tier 2 (510(k)) devices when no Tier 1 option fits, and reserve Tier 3 (361 HCT/Ps) as the lowest tier.

Tier 1: PMA/BLA/HDE — preferred when labeled indication fits.
Tier 2: 510(k) — use if Tier 1 unsuitable.
Tier 3: 361 HCT/P — reserve as lowest tier due to lack of FDA wound-etiology approval.

Documentation Required

Document that the wound bed is prepared (debridement, clean, moisture balance, infection control)

Documentation supporting authorization and coverage must show a prepared wound bed—adequate debridement, clean appearance, moisture balance—absence of active infection, management of the wound cause, and objective perfusion assessment meeting indication thresholds.

Record recent debridement and wound bed condition.
Document no clinical signs of active infection and perfusion metrics (e.g., toe pressure, TcPO2, SPP) as appropriate.

Documentation Required

Document FDA labeling compatibility and that foundational care measures are provided

To support coverage, providers must document that the chosen product is compatible with FDA labeling for the wound and that required foundational care (offloading, sustained compression, perfusion assessment, debridement, moisture/infection management) has been provided or is in place.

State the product's FDA-labeled indication and confirm the patient/wound meets that labeling.
Document foundational care measures specific to the wound etiology.

Documentation Required

Document wound type, duration, and adherence to foundational care (offloading/compression)

Providers must document wound type, wound duration/chronicity, and adherence to foundational care measures—specifically offloading for diabetic foot ulcers and sustained therapeutic compression for venous leg ulcers—along with perfusion, debridement, and infection control details.

Wound type and anatomy (e.g., DFU, VLU) and absence of exposed tendon/muscle/capsule/bone unless labeling permits.
Duration per product-specific thresholds (e.g., Apligraf ≥3 weeks; Dermagraft ≥6 weeks).
Evidence of adherence to offloading or sustained compression, plus perfusion and debridement records.

Denial Risk

Use is investigational/not medically necessary when foundational care is undocumented or other exclusions apply

Use is investigational and not medically necessary when required foundational care (e.g., documented offloading for DFU or sustained compression for VLU) is not provided, or when other exclusion conditions apply such as uncontrolled infection, untreated ischemia below thresholds, unprepared wound bed, known hypersensitivity, simultaneous multiple products, or <50% area reduction after 4 weeks of product use.

Lack of documented offloading for DFU or sustained compression for VLU makes use not medically necessary.
Other exclusion triggers: uncontrolled infection, ischemia below defined thresholds, unprepared wound bed, hypersensitivity, simultaneous use of multiple products, <50% area reduction at 4 weeks.

Denial Risk

Foundational care requirement — inadequate offloading or lack of compression risks denial

Foundational care is required; inadequate offloading for diabetic foot ulcers or lack of sustained therapeutic compression for venous leg ulcers may trigger coverage denial.

Offloading must be evidence-based and documented.
Sustained therapeutic compression must be continued during treatment for VLU.

Denial Risk

Do not apply advanced products before product-specific minimum wound duration (Apligraf ≥3 weeks; Dermagraft/Omnigraft ≥6 weeks)

Application of advanced products before meeting the product-specific minimum wound duration is not eligible—for example, Apligraf requires at least 3 weeks of wound chronicity for diabetic foot ulcers; Dermagraft and Omnigraft require at least 6 weeks—prior authorization and coverage determinations will reference these minimums.

Apligraf for DFU: at least 3 weeks before use.
Dermagraft and Omnigraft for DFU: at least 6 weeks before use.

Denial Risk

Ulcers with exposed tendon, muscle, capsule, or bone are ineligible unless labeling permits

Application of skin substitutes to ulcers with exposed tendon, muscle, joint capsule, or bone is not eligible unless the product's FDA labeling explicitly permits use; submissions must document labeling support or the request will be considered not eligible.

Any ulcer with exposed tendon/bone/joint capsule is ineligible unless FDA labeling explicitly permits the product.
Optimize surgical coverage first if labeling does not permit use.

Exclusion unless labeledUlcers with exposed deep structures are excluded unless product labeling explicitly permits use.

Foundational care requiredRequired foundational care includes offloading for DFU, sustained therapeutic compression for VLU, adequate perfusion assessment, debridement as needed, moisture balance, and infection management.

Thermal burns (policy scope)

Thermal burn depths in scopeScope includes partial-thickness, deep partial-thickness (when requiring surgery), full-thickness, and extensive burns per FDA labeling for each product.

Use conditionsProducts may be used after appropriate excision and hemostasis, with no burn wound infection present, when autograft is unavailable or being staged, and for temporary coverage or donor‑site optimization per labeling.

Label alignmentUse must align with FDA-defined depths and each product's labeling regarding burn indications.

Tier 1 — PMA/BLA/HDE labeled wound products

Regulatory definitionTier 1 includes products with FDA Premarket Approval (PMA), Biologics License Application (BLA), or Humanitarian Device Exemption (HDE) and labeled wound indications.

Preferred useTier 1 products are preferred when clinically appropriate as part of the stepwise selection approach.

Examples noted elsewhereSpecific Tier 1 examples include bilayer living cell constructs and dermal regeneration templates mapped in the product table.

Tier 2 — 510(k) cleared wound management devices

Regulatory definitionTier 2 consists of devices cleared via 510(k) for wound management indications based on substantial equivalence.

When to useUse Tier 2 devices when a Tier 1 product is unsuitable for the wound or patient.

Representative productsXenogenic/acellular matrices (e.g., OASIS, Kerecis) are examples used when Tier 1 is unsuitable.

Tier 3 — HCT/Ps regulated under section 361 without FDA wound‑etiology approval

Regulatory definitionTier 3 includes human cells, tissues, and cellular and tissue-based products regulated under section 361 without FDA wound-etiology approval.

Evidence/regulatory statusTier 3 products lack FDA approval for specific wound etiologies and are reserved as lowest tier in the stepwise approach.

Clinical implicationTier 3 should be considered only after Tier 1 and Tier 2 options have been evaluated or when labeling/support justify use.